Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12553391 | 1.00 | MCHR1 (0.34) | MCHR1MAPTROCK1BTKKDM1A | |
| SCHEMBL12553396 | 0.93 | NPC1 (0.36) | MCHR1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3694385 | 0.93 | NPC1 (0.36) | MCHR1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17656079 | 0.89 | BTK (0.32) | MCHR1MAPTBTKKDM1ARARB | |
| SCHEMBL9968003 | 0.88 | FGFR1 (0.35) | MCHR1MAPTROCK1BTKKDM1A | |
| SCHEMBL1332389 | 0.88 | FGFR1 (0.35) | MCHR1MAPTROCK1BTKKDM1A | |
| SCHEMBL16021434 | 0.87 | ROCK1 (0.33) | MCHR1MAPTROCK1BTKKDM1A | |
| SCHEMBL16011348 | 0.87 | ROCK1 (0.33) | MCHR1MAPTROCK1BTKKDM1A | |
| SCHEMBL2015558 | 0.86 | FGFR1 (0.34) | MAPTBTKRARBRARARARG | |
| SCHEMBL12573739 | 0.86 | CTNNB1 (0.36) | MAPTBTKKDM1ARARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718754-B1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-2969499-B1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2969468-B1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3045971-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2652553-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20140265010-A1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140264979-A1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-8649081-B1 | Photochromic article having two at least partially crossed photochromic-dichroic layers | TRANSITIONS OPTICAL, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8545015-B2 | Polarizing photochromic articles | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8518546-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120120473-A1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110143141-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110143141-A1 | Photochromic compounds and compositions | CCNA1, CRY1, CCNT1 | MCHR1 371/4885MAPT 785/4885ROCK1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.